Related Experiment Video
Updated: Jan 28, 2026

miRNA Expression Analyses in Prostate Cancer Clinical Tissues
Published on: September 8, 2015
MicroRNA-200a suppresses prostate cancer progression through BRD4/AR signaling pathway
Han Guan1, Zonghao You2, Can Wang2
1Department of Urology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, China.
Abstract:
Prostate cancer is still considered a significant health care challenge worldwide due in part to the distinct transformation of androgen-dependent prostate cancer (ADPC) into treatment-refractory castration-resistant prostate cancer (CRPC). Consequently, there is an urgent need to explore novel molecular mechanisms underlying treatment resistance in ADPC. Although numerous studies have alluded to the role of miR-200a in several cancers, the biological significance of miR-200a in prostate cancer remains unknown. After performing microarray analysis and reanalysis of the publicly available Memorial Sloan Kettering Cancer Center dataset, miR-200a expression was found higher in ADPC tissues and its expression was positively associated with survival of CRPC patients. In vitro studies showed that miR-200a overexpression in CRPC cells markedly suppressed cellular proliferation and facilitated apoptosis. In vivo studies indicated that overexpression of miR-200a inhibited growth and metastasis of prostate cancer. The luciferase reporter assay demonstrated that BRD4 is a direct target gene of miR-200a and it could reverse miR-200a-mediated biological effects in prostate cancer cells. Most importantly, our findings indicated that miR-200a suppresses the progression of CRPC by inhibiting the activation of BRD4-mediated AR signaling. This finding provides the foundation for the development of more personalized therapeutic approaches for CRPC patients.
Insights
MicroRNA-200a (miR-200a) suppresses castration-resistant prostate cancer (CRPC) progression by targeting BRD4 and inhibiting androgen receptor signaling, offering new therapeutic avenues.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Prostate cancer progression to castration-resistant prostate cancer (CRPC) presents a significant clinical challenge.
- Understanding molecular mechanisms of treatment resistance in androgen-dependent prostate cancer (ADPC) is crucial for developing new therapies.
- The role of microRNA-200a (miR-200a) in prostate cancer pathogenesis and treatment resistance is largely unexplored.
Purpose of the Study:
- To investigate the role and biological significance of miR-200a in prostate cancer, particularly in the context of ADPC to CRPC transition.
- To identify molecular targets of miR-200a and elucidate its mechanism of action in suppressing CRPC progression.
- To explore the potential of miR-200a as a therapeutic target for CRPC.
Main Methods:
- Microarray analysis of patient datasets to assess miR-200a expression in ADPC and its association with CRPC survival.
- In vitro studies involving miR-200a overexpression in CRPC cell lines to evaluate effects on proliferation and apoptosis.
- In vivo xenograft models to assess the impact of miR-200a on tumor growth and metastasis.
- Luciferase reporter assays to confirm BRD4 as a direct target of miR-200a.
Main Results:
- miR-200a expression was elevated in ADPC and positively correlated with CRPC patient survival.
- Overexpression of miR-200a significantly inhibited CRPC cell proliferation, induced apoptosis, and suppressed tumor growth and metastasis in vivo.
- BRD4 was identified as a direct target of miR-200a, and its inhibition reversed miR-200a's anti-cancer effects.
- miR-200a suppresses CRPC progression by inhibiting BRD4-mediated androgen receptor (AR) signaling.
Conclusions:
- miR-200a plays a critical role in suppressing prostate cancer progression, particularly CRPC.
- Targeting miR-200a or its downstream effector BRD4 presents a promising strategy for overcoming treatment resistance in CRPC.
- These findings provide a foundation for developing personalized therapeutic approaches for CRPC patients.
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
MicroRNAs
Notch Signaling Pathway
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not...
Hedgehog Signaling Pathway
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Non-Canonical Wnt Signaling Pathways

